Assuming a very good Ph 3 outcome they may consider trying to take a mCRC drug to market in their own right, at a cost of around $50 million - which would need a capital raising. And then, extra cash would be needed to progress other oncology prospects, plus VAST. When I asked ACL several months back, it was 'suggested' that there was no appetite to revisit a NASDQ listing/raising. Perhaps that's changed? There are far more knowledgable people on HC than me, but I'd think if (repeat "if") the mCRC trial is a winner, may be best if they did a fairly quick licensing deal for mCRC; and then a smaller capital raising to advance other products
- Forums
- ASX - By Stock
- trading opportunity
Assuming a very good Ph 3 outcome they may consider trying to...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online